International Journal Of Drug Delivery Technology
Volume 16, Issue 11s, 2026 | PG 537-553 | Article No 54

Liposomal Nanocochleates: A Comprehensive Review Of Formulation Strategies And Therapeutic Applications In Cancer And Diabetes

Vikas Keshavrao Mirashe1*, Prashant Kumar Dhakad2

1PhD Scholar, Department of Pharmacy, Suresh Gyan Vihar University, Jaipur, 302017 Rajasthan

2Professor, Gyan Vihar School of Pharmacy, Suresh Gyan Vihar University, Jaipur, 302017 Rajasthan

*Corresponding author: Vikas Keshavrao Mirashe, PhD Scholar, Department of Pharmacy, Suresh Gyan Vihar University, Jaipur, 302017 Rajasthan. Email: vikaskmirashe@gmail.com


ABSTRACT

Liposomal nanocochleates (NCs) represent a novel group of lipid-based nanoformulation with the specific spiral structure of these vectors, formed by stacking multilayers through the interaction between divalent cations (Ca^2+ are the most widely used in our experiments) and negatively charged phospholipids. Since they are generally composed of solid lipid bilayer sheets rather than rolling-up without inside aqueous space into large tubular structures, these as-fabricated cylindrical nanostructures demonstrate better stability compared to liposomes and effectively protect encapsulated drugs from degradation and external adverse environment. In this review, we discuss recent formulation strategies for preparation of liposomal nanocochleates [using hydrogel method, trapping method, dialysis methods (A-DSD and SAD-DMD), and new direct lipid–drug bridging techniques] and critically review their therapeutic potential in both antitumor action against cancer as well as treatment of diabetes. In the field of oncology, chemotherapeutics and phytochemicals encapsulated in nano-cochleates have shown improved oral bioavailability, enhanced tumor targeting and efficacy even to multidrug resistant cancers. Similarly, for diabetes management, nanocochleates have been employed for targeted delivery of antidiabetic drugs (metformin, insulin, resveratrol) with improved stability and controlled release properties and prolonged therapeutic action. Despite encouraging preclinical data in those 2 settings, translation has been poor. We outline priority research areas, including scalable manufacturing and long-term safety data, as well as preclinical evaluations that must be addressed by the field to pave its path towards clinical (ie, nanocochleate) based therapy of cancer and diabetes.

Keywords: Nanocochleates; Liposomes; Drug Delivery; Cancer Therapy; Diabetes; Controlled Release; Oral Bioavailability; Nanocarriers.

How to cite this article: Mirashe VK, Dhakad PK. Liposomal Nanocochleates: A Comprehensive Review of Formulation Strategies and Therapeutic Applications in Cancer and Diabetes. Int J Drug Deliv Technol. 2026;16(11s): 537-553. DOI: 10.25258/ijddt.16.11s.54

Source of support: Nil.

Conflict of interest: None